{"product_id":"ibrx-five-forces","title":"(IBRX) ImmunityBio, Inc. Porters Five Forces Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis ImmunityBio, Inc. Porter's Five Forces Analysis helps you understand the competitive pressures shaping the company, including rivalry, buyer power, supplier power, substitutes, and new entrants. What you see here is a real preview of the actual report, so you can review the content before buying. Purchase the full version for the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSuppliers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized raw materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunityBio relies on niche biologics inputs like cytokines, antibodies, vectors, and GMP-grade consumables, so supplier power stays high. These items come from a small pool of validated vendors that must meet FDA and GMP rules, and switching can trigger requalification, testing, and process changes. That makes delays and price hikes more likely when a key input is scarce.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCDMO and manufacturing dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunityBio, Inc. depends on CDMOs for complex biologics and cell therapies, so supplier power is high. Qualified capacity stays tight for late-stage programs, and quality and tech-transfer demands can push up costs and delay scale-up. That leaves ImmunityBio, Inc. with less room to negotiate price, slots, or turnaround terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory-grade quality requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers with cGMP-ready systems, full traceability, and complete batch records are scarce, so ImmunityBio, Inc. faces a tighter vendor pool and stronger incumbent pricing power. A single quality miss can stall a trial batch or FDA filing, making reliable suppliers a strategic necessity rather than a swap-in option.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProprietary technology licensors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunityBio, Inc. depends on licensed external technologies and assets, so proprietary technology licensors have above-average bargaining power. These deals can carry royalties, milestone payments, and field limits, which gives licensors leverage beyond a normal supplier contract.\u003c\/p\u003e\n\u003cp\u003eThat matters because access to differentiated platforms can shape ImmunityBio, Inc.'s R\u0026amp;D speed and product scope. If a key license is restricted or repriced, the hit can be material, especially when commercialization depends on a small set of specialized rights.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRoyalties can lift unit costs.\u003c\/li\u003e\n\u003cli\u003eMilestones shift cash timing.\u003c\/li\u003e\n\u003cli\u003eField limits can narrow growth.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLimited bargaining due to dual sourcing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunityBio, Inc. can cut supplier power when it has backup vendors or can pull steps in-house, but dual sourcing is tougher in advanced biologics and personalized cell therapy. In GMP biologics, every new vendor can trigger revalidation, so scarce qualified capacity keeps supplier leverage moderate to high.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBackup vendors reduce leverage\u003c\/li\u003e\n\u003cli\u003eRevalidation slows switching\u003c\/li\u003e\n\u003cli\u003eValidated capacity stays scarce\u003c\/li\u003e\n\u003cli\u003ePower remains moderate to high\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunityBio Faces High Supplier Power and Tight Biologics Capacity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupplier power is high for ImmunityBio, Inc. because it depends on scarce GMP-grade inputs, CDMOs, and licensed technologies, and each switch can force revalidation, testing, and delays. That leaves less room to push back on price, timing, or capacity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003eEffect\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValidated vendors\u003c\/td\u003e\n\u003ctd\u003eLimited pool\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO capacity\u003c\/td\u003e\n\u003ctd\u003eTight for biologics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitching cost\u003c\/td\u003e\n\u003ctd\u003eRequalification needed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensors\u003c\/td\u003e\n\u003ctd\u003eRoyalty leverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eUncovers ImmunityBio, Inc.’s competitive pressures, supplier and buyer power, entry risks, and substitute threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuickly spot competitive pressures on ImmunityBio, Inc. and turn strategic uncertainty into clear action.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clean source trail for ImmunityBio, Inc., making the analysis credible, easy to verify, and useful for faster investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFew direct buyers today\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunityBio has just 1 approved product and still limited commercial sales, so it does not face a broad retail buyer base yet. Near-term buyers are mainly trial sites, investigators, and later hospital systems or payers, which keeps direct buyer power low in development. That said, once sales scale, institutional buyers can press on price and access, especially in the U.S. oncology market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh payer influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFor ImmunityBio, Inc., payer power is high because if a therapy is approved, insurers, Medicare, and health systems can still decide how fast it gets used. In 2026, Medicare covered about 66 million people, so coverage rules, cost-effectiveness proof, and budget-impact data can shape adoption, and buyers can also restrict access or push for discounts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician and hospital gatekeepers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhysician and hospital gatekeepers matter most in oncology, where they steer therapy choices and prefer drugs with clear efficacy, simple use, and strong safety data. ImmunityBio’s ANKTIVA won FDA approval in 2024 for BCG-unresponsive NMIBC, backed by a 71% complete response at 3 months in QUILT 3.032, but adoption still depends on clinic logistics and outcomes in real use. If administration is complex or results look uneven, these gatekeepers can slow uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTrial enrollment sensitivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunityBio, Inc. faces high trial enrollment sensitivity because patients and sites can slow or speed enrollment in ongoing studies. Competing trials, strict eligibility rules, and limited geography access can delay recruitment, which raises development time and cost and gives customers more leverage over trial pace.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSite and patient access can bottleneck enrollment\u003c\/li\u003e\n\u003cli\u003eCompeting studies cut recruitment speed\u003c\/li\u003e\n\u003cli\u003eSlow enrollment raises trial cost and duration\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAlternative treatment choice\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn oncology and infectious disease, buyers can often switch among several standard-of-care options, so ImmunityBio, Inc. must show clear clinical upside to win pricing power. If its therapies do not beat existing treatments on response, safety, or durability, payers and providers will favor the cheaper or better-known choice, keeping customer power moderate to high.\u003c\/p\u003e\n\u003cp\u003eThat pressure is real in bladder cancer, where current non-surgical options already include established drugs and procedures. So, unless ImmunityBio, Inc. proves a step-change benefit, alternative treatment choice caps premium pricing and makes reimbursement tougher.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMany standard-of-care options already exist\u003c\/li\u003e\n\u003cli\u003eClear superiority is needed for premium pricing\u003c\/li\u003e\n\u003cli\u003ePayers can push back on weak differentiation\u003c\/li\u003e\n\u003cli\u003eCustomer power stays moderate to high\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Today, Rising Fast: Payer Power Challenges ImmunityBio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomer power for ImmunityBio, Inc. is low in development but rises fast after launch. In 2026, Medicare covered about 66 million people, so payers can still block access, demand discounts, or slow uptake. For ANKTIVA in BCG-unresponsive NMIBC, physicians and hospitals also shape use, and any weak real-world benefit can cap pricing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare reach\u003c\/td\u003e\n\u003ctd\u003e~66 million lives\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eANKTIVA proof\u003c\/td\u003e\n\u003ctd\u003e71% CR at 3 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eImmunityBio, Inc. Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact ImmunityBio, Inc. Porter's Five Forces Analysis you'll receive after purchase—no placeholders, no edits, just the final document. It’s a fully written, professionally formatted report ready for immediate use. What you see here is the same file you’ll download instantly after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRivalry Among Competitors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCrowded oncology landscape\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunityBio, Inc. competes in one of biotech’s toughest arenas: cancer immunotherapy. Large pharma, mid-cap biotechs, and platform players are all chasing the same tumor types and mechanisms, so rivalry stays intense. With dozens of approved and late-stage checkpoint, cell, and cytokine programs in the market, rivals can move fast on data, labels, and partnerships.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultiple pipeline rivals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunityBio faces heavy rivalry because its bladder, pancreatic, and lung cancer programs are up against many late-stage rivals, including drugs already on the market. Merck’s Keytruda posted $29.5 billion in 2024 sales, and AstraZeneca’s Imfinzi reached $4.7 billion, showing how deep the bench is. That means ImmunityBio must prove clear gains in efficacy, safety, or speed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFast science and trial pace\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiotech rivalry is intense because a single Phase 3 readout, FDA milestone, or licensing deal can reprice a drug program overnight. ImmunityBio’s Anktiva won FDA approval in April 2024, showing how fast one approval can shift market attention. With competitors racing through trials and regulators, the field stays highly dynamic and unforgiving.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePlatform overlap\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunityBio’s immune-oncology mix overlaps with other next-gen cancer platforms, including NK-cell, vaccine, and other cell-therapy programs. With ANKTIVA as its first approved product, it still competes with firms chasing the same pathways and tumor types, which raises head-to-head pressure for trial sites, partners, and capital.\u003c\/p\u003e\n\u003cp\u003eThat overlap matters because oncology deal flow is crowded: 100+ cell-therapy and immunotherapy assets have been in active clinical development across major biotech players, so investor attention can shift fast to the latest data readout.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame targets, same patients.\u003c\/li\u003e\n\u003cli\u003eFiercer fight for investigators.\u003c\/li\u003e\n\u003cli\u003eHarder to win partner mindshare.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHigh switching among innovation leaders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompetitive rivalry is high because physicians, hospitals, and payers shift fast to the most proven and simplest options. In immuno-oncology, evidence can change in months, so leadership can move quickly even when products are not direct copies. ImmunityBio, Inc.’s ANKTIVA got its first FDA approval in April 2024, but it still competes in a market where validation drives adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFast evidence shifts raise churn risk.\u003c\/li\u003e\n\u003cli\u003eEase of use can beat product gaps.\u003c\/li\u003e\n\u003cli\u003eApril 2024 approval is still early.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunityBio Faces Fierce Oncology Competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry is high because ImmunityBio, Inc. fights for the same oncology patients, trial sites, and payers as much larger drug makers. Merck’s Keytruda hit $29.5 billion in 2024 sales, and AstraZeneca’s Imfinzi reached $4.7 billion, showing how crowded the field is. ANKTIVA’s April 2024 FDA approval helps, but rivals can still win fast on better data and simpler use.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey rival\u003c\/th\u003e\n\u003cth\u003e2024 sales\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKeytruda\u003c\/td\u003e\n\u003ctd\u003e$29.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImfinzi\u003c\/td\u003e\n\u003ctd\u003e$4.7B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eANKTIVA\u003c\/td\u003e\n\u003ctd\u003eFirst FDA approval: Apr 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSubstitutes Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard-of-care therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThreat from substitutes is high because ImmunityBio, Inc. faces five standard-of-care options: chemotherapy, radiation, surgery, targeted therapy, and existing immunotherapies. These are already entrenched and often reimbursed, so doctors can switch fast if outcomes lag or toxicity is worse. In oncology, one weaker response rate or safety signal can push patients back to these proven alternatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompeting biologic platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompeting biologic platforms raise the substitution risk for ImmunityBio, Inc. because checkpoint inhibitors, bispecifics, cell therapies, and vaccines can target the same cancer patients and hospital budgets. More than 10 PD-1\/PD-L1 checkpoint drugs are already approved across major markets, so switching options are broad.\u003c\/p\u003e\n\u003cp\u003eThis means payers and oncologists can choose among many biologic paths, even when the science differs. If a rival platform offers similar survival or response gains with better dosing or cost, it can win share fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCombination therapy alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCombination therapy is a real substitute risk for ImmunityBio, Inc. in oncology, because doctors can pair already approved drugs and get usable outcomes without adopting a new platform. In 2025, the U.S. oncology drug market kept favoring regimens with proven survival data, and many cancers now use 2- or 3-drug combinations as standard care. If approved pairs match or beat a new candidate on efficacy, safety, or cost, demand can shift away fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSupportive care and watchful waiting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSupportive care and watchful waiting are real substitutes for ImmunityBio, Inc.'s experimental therapies when benefit is unclear or toxicity risk is high. In oncology, many patients still choose symptom control or monitoring, especially in later-line settings, so the switch to a new drug is not automatic. That slows uptake and pressures pricing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLower urgency when outcomes are uncertain\u003c\/li\u003e\n\u003cli\u003eHigh side effects favor palliative care\u003c\/li\u003e\n\u003cli\u003eMonitoring can delay treatment adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical evidence as the switch point\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSubstitution pressure for ImmunityBio, Inc. stays moderate to high because doctors can fall back on standard cancer care if ImmunityBio, Inc.'s candidates do not prove better on response, durability, or tolerability. The key switch point is hard clinical proof, like the FDA-approved ANKTIVA label for BCG-unresponsive NMIBC in April 2024, and stronger later data would be needed to widen use. Without clear gains, payers will favor familiar, lower-risk options.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinical proof drives switching.\u003c\/li\u003e\n\u003cli\u003eDurability matters as much as response.\u003c\/li\u003e\n\u003cli\u003eWeak data keeps substitution high.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Substitution Risk for ImmunityBio in Oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of substitutes is high for ImmunityBio, Inc. because oncology buyers can switch to surgery, chemo, radiation, targeted drugs, or approved immunotherapies. More than 10 PD-1\/PD-L1 drugs are already approved, and 2- or 3-drug regimens often stay the default in 2025. If efficacy, safety, or cost is weaker, payers can shift fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSubstitute\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePD-1\/PD-L1 drugs\u003c\/td\u003e\n\u003ctd\u003e10+ approved\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eANKTIVA\u003c\/td\u003e\n\u003ctd\u003eFDA label Apr 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUse pattern\u003c\/td\u003e\n\u003ctd\u003e2- or 3-drug regimens\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEntrants Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh capital requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunityBio, Inc. faces a high barrier because biologic and cell therapy programs can require hundreds of millions of dollars before launch; a single Phase 3 program often costs $20 million to $100 million, and GMP manufacturing can add tens of millions more. The FDA said 2025 still had 100+ cell and gene therapy trials active in the U.S., so capital needs stay intense. This makes new entrants rare and slow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and trial barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunityBio’s path shows the barrier: ANKTIVA won FDA approval in 2024 after years of Phase 1-3 work, and the company still reported $33.5 million in Q1 2025 revenue and a $115.7 million net loss, showing how costly proof is. New biotech entrants must clear long FDA review, safety checks, and multi-phase data demands, so only a few survive.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdvanced immunotherapies need cGMP suites, tight QC, and cold-chain handling, so new entrants face long build times and high fixed costs; stand-up can take 18-36 months and run into tens of millions of dollars. Outsourcing can speed launch, but it still ties entrants to scarce CDMO slots and expert staff. For ImmunityBio, Inc., that supply bottleneck keeps the threat of new entrants lower.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIP and licensing barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunityBio operates in a patent-heavy field, so new entrants need licenses, freedom-to-operate reviews, and time to avoid infringement claims. That raises legal cost and slows launch. Strong IP around cell therapies, biologics, and manufacturing know-how makes entry harder.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatent walls lift entry costs.\u003c\/li\u003e\n\u003cli\u003eLicensing delays new launches.\u003c\/li\u003e\n\u003cli\u003eLitigation risk deters small firms.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTalent and partnership scarcity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTalent and partnership scarcity raises the bar for any new entrant in ImmunityBio, Inc.'s space. Top immuno-oncology scientists, clinical investigators, and trial sites are already tied up with large peers, so a newcomer must win the same scarce expertise and infrastructure, which slows entry even when capital is available.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKey talent is already locked in\u003c\/li\u003e\n\u003cli\u003eTrial sites are capacity constrained\u003c\/li\u003e\n\u003cli\u003ePartner access is slow and costly\u003c\/li\u003e\n\u003cli\u003eEntry is possible, but not fast\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eImmunityBio, Inc. competes in a field where drug development is expensive and execution-heavy: the median oncology trial can enroll hundreds of patients and take years, so access to investigators matters as much as money. That scarcity protects incumbents and makes partner-building a real barrier.\u003c\/p\u003e\n\u003cp\u003eFor new players, the main issue is not starting the science; it is getting enough expert hands, patient sites, and credible partners to run trials at speed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunityBio Faces Low Entry Threat Amid Heavy Biotech Capital Hurdles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of new entrants is low for ImmunityBio, Inc. because biologic entry is capital-heavy: FDA said 100+ cell and gene therapy trials were active in 2025, but few firms can fund Phase 3 work, GMP buildout, and long FDA review. ANKTIVA’s 2024 approval and ImmunityBio, Inc.’s Q1 2025 $33.5 million revenue versus a $115.7 million net loss show how hard it is to reach scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBarrier\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial load\u003c\/td\u003e\n\u003ctd\u003e100+ active U.S. cell and gene therapy trials in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2025 revenue\u003c\/td\u003e\n\u003ctd\u003e$33.5 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2025 net loss\u003c\/td\u003e\n\u003ctd\u003e$115.7 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234485346569,"sku":"ibrx-five-forces","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/ibrx-five-forces.webp?v=1785721547","url":"https:\/\/dcfanalyst.com\/products\/ibrx-five-forces","provider":"DCF Analyst","version":"1.0","type":"link"}